By Fineline Cube 
China’s Shanghai Pharmaceuticals Holding Co., Ltd. (HKG: 2607, SHA: 601607; SPH) has established a partnership with Chugai Pharma China Co., Ltd. to develop more efficient and safer bone health products. The collaboration aims to integrate their respective strengths, with Chugai Pharma China contributing its R&D expertise in osteoporosis and SPH leveraging its extensive channel and market network.
Collaboration Objectives
The partnership focuses on promoting innovative orthopedic prescription drugs, including Edirol (eldecalcitol), to expand SPH’s diversified health product line and improve bone health among Chinese patients.
Company Backgrounds
Chugai Pharma China Co., Ltd., a wholly foreign-owned enterprise of Swiss giant Roche’s Japan-based subsidiary Chugai Pharmaceutical Co., Ltd. (TYO: 4519), specializes in the research and development of innovative drugs for tumors, bones and joints, autoimmune diseases, and neurological disorders. SPH, a leading modern pharmaceutical supply chain service enterprise in China, brings significant scale and network advantages to the collaboration.-Fineline Info & Tech